


Hirsh D. Trivedi¹, Ghideon Ezaz¹, Kellie Howard², Claudia Filozof³, Sally Dow², Cara Lord², Matthew Toma², Misung Kim⁴, Mark Herman⁵, Imad Nasser⁶, Margery A. Connelly⁷, Nezam H. Afdhal¹, Mark Parrish², Z. Gordon Jiang¹, Michelle Lai¹

¹Division of Gastroenterology and Hepatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA ²Covance Genomics Laboratory, Redmond, WA³Covance Clinical Services, Madrid, Spain;

⁴Division of Endocrinology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA; ⁵Division of Endocrinology, Duke University Medical Center, Durham, NC ⁶Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁷Laboratory Corporation of America® Holdings (LabCorp), Morrisville, NC;



| Patient Characteristics | | | |
|----------------------------|---------------------|--|--|
| | | | |
| Total (n) | 217 | | |
| Age (mean, IQR) | 50.9 (42.9-60.5) | | |
| Female (%) | 40.7 | | |
| Hispanic ethnicity (%) | 13.7 | | |
| BMI (mean, IQR) | 34.0 (29.6-36.7) | | |
| Diabetes (%) | 25.4 | | |
| Hypertension (%) | 38.7 | | |
| Fasting lipids (mean, IQR) | | | |
| Triglycerides | 196.3 (107-259) | | |
| LDL-C | 109.8 (83-132) | | |
| HDL-C | 45.9 (37-53) | | |
| Fibrosis stage (%) | | | |
| 0- 1 | 53.3 | | |
| 2 | 33.0 | | |
| 3-4 | 13.7 | | |
| NAS score (mean, IQR) | 4.6 (4-6) | | |
| PNPLA3 genotype (%) | | | |
| CC | 37.3 | | |
| CG | 41.2 | | |
| GG | 21.5 | | |
| TM6SF2 genotype (%) | | | |
| CC | 79.7 | | |
| CT or TT | 20.3 | | |
| eLP-IR score (mean, IQR) | 66.3 (54.4-83.0) | | |
| ADA2 (mean, IQR) | 6.8 (4.1-8.3) | | |
| CK18 (mean, IQR) | 377.3 (135.8-518.0) | | |

Differential regulation of microRNAs in nonalcoholic fatty liver disease

Abstract

Background & Aims:

Nonalcoholic fatty liver disease (NAFLD) is a heterogeneous disease driven by both genetic and environmental factors. Several microRNAs (miRNA) have been implicated in the pathogenesis of NAFLD. We aimed to examine the differential relationship between a panel of miRNAs (miR-34a, miR-122, miR-191, miR-192, and miR-200a) and NAFLD disease phenotype as well as genetic and metabolic factors related to NAFLD pathogenesis.

Methods:

A total of 170 subjects with biopsy proven NAFLD from a prospective NAFLD registry were included in the study. The levels of target miRNAs and housekeeping controls were measured by qPCR using plasma samples from patients in the biorepository. We studied the relationship between the miRNA levels and histological features of NAFLD, NAFLDrelated genotypes, insulin resistance measured by the enhanced Lipoprotein Insulin Resistance Index (eLP-IR), and the activity of adenosine deaminase 2 (ADA2), a marker of macrophage activation.

Results:

Four of the miRNAs: miR-34a, miR-122, miR-192 and miR-200a, were strongly correlated with the stage of liver fibrosis with each stage of fibrosis associated with 0.26 to 0.44 standard deviation (SD) increases in miRNA concentration in the plasma (all p values < 0.001). While miR-34a, miR-122, miR-192 and miR-200a were associated with ballooning degeneration, , only miR-34a, miR-122 and miR-192 were associated with hepatic steatosis and lobular inflammation. These observations were mirrored by a robust association between eLP-IR, a measure of insulin resistance, and miR-34a, miR-122 and miR-192 (p values < 0.001 – 0.002). The GC and GG variants at rs738409 of PNPLA3 were associated with the higher levels of miR-34a, miR-122, and miR-192, but not miR-200a, whereas the CT and TT variants at rs58542926 of TM6SF2 were associated with the higher levels of miR-34a, miR-122, and miR-200a, but not miR-192. Finally, miR-34a and miR-200 were associated with an elevated activity of ADA2. In contrast, miR-191 was not found to be associated with NAFLD histological phenotype, insulin resistance, the PNPLA3 and TM6SF2 genotypes or inflammation as measured by ADA2 and CK-18.

Conclusions:

Four miRNAs demonstrated differential associations with various pathogenic factors in NAFLD, suggesting their distinctive pathways of activation. Our study suggests that circulating miRNAs are potential biomarkers to characterize subtypes of NAFLD patients.

Conclusions

- AFLD is a heterogeneous disease with influence from genetics, insulin resistance and immune dysregulation
- MiRNAs correlate differentially with risk factors of NAFLD, disease activity, and progression
- MiRNAs can potentially be used as tools to help predict NAFLD phenotypes that influence disease severity

| Table 1 | | | | | |
|--------------|---------------------|-------------------|------------|------------|------------|
| | | | | | |
| | miR-34a | miR-122 | miR-192 | miR-200a | miR-191 |
| | β^1 , p value | β , p value | β, p value | β, p value | (control) |
| | | | | | β, p value |
| eLP-IR score | 0.012 | 0.011 | 0.011 | 0.002 | 0.001 |
| | <0.001 | 0.001 | 0.002 | 0.7 | 0.7 |
| BMI | 0.009 | 0.002 | -0.012 | -0.010 | -0.012 |
| | 0.5 | 0.9 | 0.3 | 0.5 | 0.3 |
| Diabetes | 0.728 | 0.154 | 0.354 | 0.464 | -0.009 |
| | <0.001 | 0.4 | 0.04 | 0.01 | 1.0 |
| Dyslipidemia | | | | | |
| TG | 0.001 | 0.002 | 0.002 | 0.001 | -0.0001 |
| | 0.07 | 0.03 | 0.002 | 0.2 | 0.9 |
| LDL-C | -0.002 | -0.001 | -0.0003 | -0.002 | 0.003 |
| | 0.3 | 0.7 | 0.9 | 0.5 | 0.2 |
| HDL-C | -0.014 | -0.015 | -0.014 | 0.004 | -0.009 |
| | 0.03 | 0.02 | 0.02 | 0.6 | 0.1 |
| Hypertension | 0.496 | 0.033 | 0.097 | 0.374 | -0.088 |
| | 0.001 | 0.8 | 0.523 | 0.03 | 0.6 |
| ADA2 | 0.104 | 0.064 | 0.062 | 0.101 | 0.016 |
| | <0.001 | 0.02 | 0.02 | 0.001 | 0.6 |
| CK18 | 0.002 | 0.001 | 0.002 | 0.0004 | -0.0002 |
| | <0.001 | <0.001 | <0.001 | 0.09 | 0.3 |

Univariate associations between miRNA and non-genetic pathogenic factors in NAFLD.

| | miR-34a | miR-122 | miR-192 | miR-200a | miR-19 ² |
|--------------|---------------------|------------|--------------------------|-------------------|---------------------|
| | β^1 , p value | β, p value | β , p value | β, p value | (control |
| | | | | | β , p valu |
| eLP-IR score | 0.010 | 0.009 | 0.012 | 0.007 | 0.003 |
| | 0.035 | 0.050 | 0.011 | 0.2 | 0.5 |
| PNPLA3 | | | | | |
| CC | Ref | Ref | Ref | Ref | Ref |
| CG or | 0.689 | 0.788 | 0.770 | 0.397 | 0.204 |
| GG | 0.001 | <0.001 | <0.001 | 0.1 | 0.4 |
| TM6SF2 | | | | | |
| CC | Ref | Ref | Ref | Ref | Ref |
| CT or TT | 0.545 | 0.204 | 0.359 | 0.344 | -0.294 |
| | 0.025 | 0.4 | 0.1 | 0.2 | 0.3 |
| ADA2 | .087 | 0.057 | 0.050 | 0.100 | 0.022 |
| | 0.001 | 0.027 | 0.049 | 0.001 | 0.4 |

NAFLD

| Table 3 | | | | | |
|---|-----------------------|-----------------------|-----------------------|------------------------|------------------------------------|
| | miR-34a β, p value | miR-122 β, p value | miR-192 β, p value | miR-200a β, p value | miR-191 (control) β, p value |
| Fibrosis | 0.445 | 0.264 | 0.315 | 0.271 | -0.019 |
| | <0.001 | <0.001 | <0.001 | <0.001 | 0.8 |
| Steatosis | 0.363 | 0.415 | 0.367 | 0.116 | -0.018 |
| | 0.001 | <0.001 | 0.001 | 0.3 | 0.9 |
| Lobular | 0.480 | 0.402 | 0.364 | 0.151 | -0.018 |
| inflammation | <0.001 | 0.003 | 0.007 | 0.3 | 0.9 |
| Ballooning | 0.487 | 0.404 | 0.325 | 0.330 | -0.187 |
| | <0.001 | <0.000 | 0.002 | 0.004 | 0.07 |
| Univariate associations between microRNA and histological features of NAFLD | | | | | |



